NCT07087106View on ClinicalTrials.gov

Glucose Consumption in MS Using [F-18]FDG-PET

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2026

Conditions

Multiple Sclerosis

Interventions

DRUG

[F-18]FDG

PET radiopharmaceutical

Trial Locations (1)

02115

Brigham & Women's Hospital, Boston

All Listed Sponsors

collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Brigham and Women's Hospital

OTHER